Business
Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk
Published Recently in the Journal of the American Academy of Dermatology FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nPublished Recently in the Journal of the American Academy of Dermatology\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a systematic review and meta-analysis of four study cohorts demonstrating that the DecisionDx®-Melanoma test is an independent, significant predictor of recurrence and metastatic risk in patients with invasive cutaneous melanoma.\n\n\nThe article titled, “Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients,” appeared in the Journal of the American Academy of Dermatology (JAAD).\n\n\n“This systematic review and meta-analysis are important because they further demonstrate the strength and consistency of the DecisionDx-Melanoma test as a significant, independent predictor of recurrence and metastasis in patients with Stage I-III melanoma, across these unique study cohorts,” said lead author Bradley Greenhaw, M.D., Dermatology Center of North Mississippi, Tupelo, Mississippi. “The meta-analysis shows the value of using the DecisionDx-Melanoma gene expression profile test in combination with American Joint Committee on Cancer (AJCC) staging to optimize melanoma prognostication.”\n\n\nSystematic Review and Meta-Analysis Background:\n\n\nThis study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)1.\n\n\nMultiple published archival and prospective studies have described the prognostic capability, performance and clinical utility of the DecisionDx-Melanoma test to assess recurrence risk and inform patient management decisions on sentinel lymph node recommendations, follow up, surveillance imaging and referrals for patients with cutaneous melanoma.\n\n\nThis systematic review and meta-analysis were performed to evaluate the cumulative prognostic effect of the test across multiple cohorts with a focus on differences in recurrence and distant metastasis between patients with a DecisionDx-Melanoma Class 1A (lowest risk) and Class 2B (highest risk) test result. Four study cohorts, which included a total of 1,479 non-overlapping patients with Stage I-III melanoma, were included in the analysis.\n\n\nSys...